Hsiao D. Lieu

2.0k total citations · 1 hit paper
35 papers, 1.5k citations indexed

About

Hsiao D. Lieu is a scholar working on Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Hsiao D. Lieu has authored 35 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cardiology and Cardiovascular Medicine, 10 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Molecular Biology. Recurrent topics in Hsiao D. Lieu's work include Cardiac Imaging and Diagnostics (8 papers), Liver Disease Diagnosis and Treatment (7 papers) and Heart Failure Treatment and Management (6 papers). Hsiao D. Lieu is often cited by papers focused on Cardiac Imaging and Diagnostics (8 papers), Liver Disease Diagnosis and Treatment (7 papers) and Heart Failure Treatment and Management (6 papers). Hsiao D. Lieu collaborates with scholars based in United States, United Kingdom and Taiwan. Hsiao D. Lieu's co-authors include Brent Blackburn, Luiz Belardinelli, Toufigh Gordi, Lei Ling, Stephen A. Harrison, Ann Olmsted, Alex M. DePaoli, Timothy M. Bateman, Arun J. Sanyal and Ami E. Iskandrian and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Journal of Clinical Oncology.

In The Last Decade

Hsiao D. Lieu

33 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

2020 218 citations Stephen A. Harrison, Guy Neff et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hsiao D. Lieu United States	19	550	499	356	332	267	35	1.5k
Timo Savunen Finland	21	374 0.7×	282 0.6×	334 0.9×	268 0.8×	309 1.2×	61	1.4k
Riikka Läutamaki Finland	29	722 1.3×	1.0k 2.1×	449 1.3×	430 1.3×	548 2.1×	57	2.4k
Joji Nitobe Japan	21	815 1.5×	184 0.4×	167 0.5×	366 1.1×	172 0.6×	46	1.4k
Marc J. Semigran United States	7	786 1.4×	80 0.2×	168 0.5×	645 1.9×	337 1.3×	8	1.4k
Sean Lal Australia	20	958 1.7×	97 0.2×	218 0.6×	522 1.6×	282 1.1×	68	1.5k
Hidetaka Kioka Japan	16	353 0.6×	186 0.4×	126 0.4×	281 0.8×	145 0.5×	49	879
Georg Horstick Germany	19	433 0.8×	348 0.7×	147 0.4×	117 0.4×	215 0.8×	56	1.2k
Naoki Watanabe Japan	18	573 1.0×	321 0.6×	71 0.2×	463 1.4×	190 0.7×	67	1.4k
Jiayun Shen China	18	156 0.3×	96 0.2×	998 2.8×	355 1.1×	325 1.2×	36	1.7k
Maija Mäki Finland	22	536 1.0×	1.0k 2.0×	120 0.3×	191 0.6×	504 1.9×	46	1.8k

Countries citing papers authored by Hsiao D. Lieu

Since Specialization

Citations

This map shows the geographic impact of Hsiao D. Lieu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hsiao D. Lieu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hsiao D. Lieu more than expected).

Fields of papers citing papers by Hsiao D. Lieu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hsiao D. Lieu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hsiao D. Lieu. The network helps show where Hsiao D. Lieu may publish in the future.

Co-authorship network of co-authors of Hsiao D. Lieu

This figure shows the co-authorship network connecting the top 25 collaborators of Hsiao D. Lieu. A scholar is included among the top collaborators of Hsiao D. Lieu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hsiao D. Lieu. Hsiao D. Lieu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Judy S., David Sommerhalder, Manish Sharma, et al.. (2024). Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.. Journal of Clinical Oncology. 42(16_suppl). 2582–2582. 2 indexed citations

Blum, Lisa K., Anushka De Costa, Geoffrey W. Stone, et al.. (2024). Abstract 3641: Pharmacodynamic and predictive biomarker results from the phase I dose escalation study of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumors. Cancer Research. 84(6_Supplement). 3641–3641.

Sanyal, Arun J., Lei Ling, Ulrich Beuers, et al.. (2021). Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. JHEP Reports. 3(3). 100255–100255. 63 indexed citations

Harrison, Stephen A., Guy Neff, Cynthia D. Guy, et al.. (2020). Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. Gastroenterology. 160(1). 219–231.e1. 218 indexed citations breakdown →

Loomba, Rohit, Lei Ling, Duy M. Dinh, et al.. (2020). The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology. 73(1). 126–143. 67 indexed citations

Harrison, Stephen A., Guy Neff, Cynthia D. Guy, et al.. (2020). Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis. Journal of Hepatology. 73. S114–S115. 1 indexed citations

Bae, Jay, Douglas E. Faries, Frank R. Ernst, et al.. (2014). Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. Current Medical Research and Opinion. 30(11). 2207–2216. 20 indexed citations

Rosenberg, Steven, Michael Elashoff, Hsiao D. Lieu, et al.. (2012). Whole Blood Gene Expression Testing for Coronary Artery Disease in Nondiabetic Patients: Major Adverse Cardiovascular Events and Interventions in the PREDICT Trial. Journal of Cardiovascular Translational Research. 5(3). 366–374. 20 indexed citations

Vörös, Szilárd, Michael Elashoff, Amy J. Sehnert, et al.. (2011). A VALIDATED, PERIPHERAL BLOOD GENE EXPRESSION PATTERN CORRELATES WITH CORONARY ARTERIAL PLAQUE BURDEN BY QUANTITATIVE CORONARY ANGIOGRAPHY AND CORONARY ARTERY CALCIUM SCORING. Journal of the American College of Cardiology. 57(14). E1157–E1157. 1 indexed citations

10.

Lieu, Hsiao D., James J. Young, Uri Elkayam, et al.. (2011). A PHASE II, DOSE-RANGING STUDY WITH CD-NP, A CHIMERIC NATRIURETIC PEPTIDE, IN ACUTE DECOMPENSATED HEART FAILURE PATIENTS WITH RENAL COMPROMISE. Journal of the American College of Cardiology. 57(14). E2029–E2029. 3 indexed citations

11.

Lee, Candace Y.W., Horng H. Chen, Ondřej Lisý, et al.. (2009). Pharmacodynamics Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD‐NP, in a First‐in‐Human Clinical Trial in Healthy Subjects. The Journal of Clinical Pharmacology. 49(6). 668–673. 90 indexed citations

12.

Thomas, Gregory S., et al.. (2009). The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. Journal of Nuclear Cardiology. 16(1). 63–72. 62 indexed citations

13.

Leaker, Brian, B J O'Connor, Trevor T. Hansel, et al.. (2008). Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial. Journal of Nuclear Cardiology. 15(3). 329–336. 64 indexed citations

14.

Sim, Derek, Hsiao D. Lieu, & Patrick André. (2008). Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future. Biomarker Insights. 3. 2137216940–2137216940. 3 indexed citations

15.

Iskandrian, Ami E., Timothy M. Bateman, Luiz Belardinelli, et al.. (2007). Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. Journal of Nuclear Cardiology. 14(5). 645–658. 238 indexed citations

16.

Lieu, Hsiao D., John C. Shryock, Gregory O. von Mering, et al.. (2007). Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. Journal of Nuclear Cardiology. 14(4). 514–520. 93 indexed citations

17.

Gordi, Toufigh, Brent Blackburn, & Hsiao D. Lieu. (2007). Regadenoson Pharmacokinetics and Tolerability in Subjects With Impaired Renal Function. The Journal of Clinical Pharmacology. 47(7). 825–833. 44 indexed citations

18.

Bergö, Martin O., Hsiao D. Lieu, Bryant J. Gavino, et al.. (2004). On the Physiological Importance of Endoproteolysis of CAAX Proteins. Journal of Biological Chemistry. 279(6). 4729–4736. 49 indexed citations

19.

Lieu, Hsiao D., Shannon K. Withycombe, James X. Rong, et al.. (2003). Eliminating Atherogenesis in Mice by Switching Off Hepatic Lipoprotein Secretion. Circulation. 107(9). 1315–1321. 100 indexed citations

20.

Meller, Emanuel, et al.. (1992). Comparative effects of receptor inactivation, 17 beta-estradiol and pertussis toxin on dopaminergic inhibition of prolactin secretion in vitro.. Journal of Pharmacology and Experimental Therapeutics. 263(2). 462–469. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact